There has been a dramatic increase in the incidence of diabetes worldwide,
which has been exacerbated by the growing obesity problem across the globe.
Once thought of as primarily a childhood disease--sometimes referred to as
juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to
the adoption of a high-fat, high-carbohydrate, high-calorie American diet has
resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes,
among adults across the world. As such, the global market for blood glucose
testing products is undergoing a significant transition driven by the advent
of new analytical technologies and developments in diabetes treatment.
Although the blood glucose testing segment of the in vitro diagnostics (IVD)
industry is mature, certain segments of the market, such as home testing
devices for diabetes management, will exhibit strong growth. What's more,
non-invasive testing now represents a major new area for the application of
IVD testing. Additionally, direct access testing--or over-the-counter testing,
which allows consumers to order tests themselves without visiting a
doctor--has emerged as a strong force in the blood glucose testing segment.
The purpose of this TriMark Publications report is to describe the specific
market segments for blood glucose testing and diabetes management. This study
reviews all of the generally-accepted clinical analytical methods that are
currently in use today for measuring serum or plasma or whole-blood glucose
concentrations. Moreover, it examines clinical measurement devices, reagents
and supplies as utilized in hospitals, clinics, doctor's offices and at-home
care locations. The report has made a survey of selected companies marketing,
manufacturing or developing various blood glucose testing and diabetes
management supplies throughout the world. Each company is discussed in
extensive depth with a section on its history, product line, business and
marketing analysis, and a subjective commentary of the company's market
position. Detailed tables and charts with sales forecasts and market share
data are also included.
Table of Contents
Table of Contents
1. Overview
1.1. Statement of Report
1.2. About this Report
1.3. Scope of the Report
1.4. Methodology
1.5. Executive Summary
2. Diabetes
2.1. Demographics of Diabetes
2.1.1. Worldwide Diabetes Incidence
2.1.2. Diabetes in the U.S.
2.2. Understanding the Metabolic Conditions Underlying and Associated with
Diabetes
2.2.1. Pre-Diabetes Syndrome
2.2.2. Metabolic Syndrome
2.2.3. Progression of Diabetes
2.2.4. Diabetes and Inflammation
2.2.5. Risk Factors and Diabetes
2.2.5.1. Obesity
2.2.5.2. Stress-Induced Hyperglycemia
2.2.6. Complications and Co-Morbidities in Diabetes
2.2.6.1. Preventing Complications and Co-Morbidities in Diabetes
2.2.6.2. Cardiovascular Disease Facts
2.3. Economics of Diabetes
3. Market Analysis: Size, Growth, Share and Competitors
3.1. Worldwide Glucose Testing Market
3.1.1. Global Blood Glucose Self-Testing Market
3.1.2. Worldwide Professional Blood Glucose Testing Market
3.1.3. Continuous Glucose Monitoring Markets
3.2. U.S. Market
3.2.1. U.S. Over-the-Counter (OTC) Self-Testing Glucose Market
3.2.2. U.S. Professional Glucose Testing Market
3.3. European Market
3.4. Asian Market
3.4.1. Japanese Market
3.4.2. Chinese Market
3.4.3. Indian Market
3.4.4. Korean Market
3.4.5. Southeast Asian Market
3.4.6. ROW Markets
3.5. Competitive Situation
3.5.1. Key Players
3.5.2. Analyses of the Current Market Conditions, Competition and
Product Mix
3.6. Market Drivers and Restraints
3.6.1. Market Drivers
3.6.2. Market Restraints
3.7. Market and Product Trends
3.7.1. Market Trends
3.7.2. Technology Trends
3.8. Strategic Recommendations
3.9. Competitive Strategies
3.10. Adjacent Markets
4. Glucose Diagnostic and Monitoring Recommendations
4.1. Diagnosis of Diabetes Mellitus
4.2. Tight Glucose Control in Treating Diabetes
4.3. Recommendations for Glucose Control in Diabetic Patients
4.3.1. Recommended Frequency of Blood Glucose Testing
4.3.2. Using Blood Glucose Data to Monitor and Modify Patient Therapy
4.3.3. Testing in Individuals with Type 2 Diabetes
4.3.4. Continuous Glucose Monitoring (CGM)
4.3.5. A1c Testing Recommendations
4.4. Hypoglycemia and Treatment
5. Glucose Testing Technology Platforms and Consumable Products
5.1. Types of Glucose Determination Technologies
5.2. Enzymatic Reactions Used to Determine Glucose Concentrations
6.9.5. Medtronic and Bayer Healthcare Expand International Alliance
6.9.6. Medtronic Opens New Diabetes Center In San Antonio
6.9.7. Abbott Diabetes Care Announces Recall of Certain Lots of
Precision XtraR, Precision Xceed ProR, MediSenseR Optium, Optium,OptiumEZ
and ReliOnR Ultima Blood Glucose Test Strips in the United States and Puerto
Rico
6.9.8. Abbott Receives FDA Clearance for New, Easier-to-Use FreeStyle
LiteR Test Strips
6.9.9. DexCom Receives CE Mark Approval for the SEVENR Continuous
Glucose Monitoring System
6.9.10. iBGStar Blood Glucose Monitoring System Receives U.S. FDA 510(k)
Clearance
6.9.11. PositiveID Corporation and IDEAL LIFE Partner to Bring iglucose
to Market for Wireless Diabetes Management
6.9.12. Roche Diagnostics U.S. and DexCom, Inc. Announce Research and
Development Agreement
6.10. M&A Activity
6.10.1. Home Diagnostics, Inc. and Nipro Diabetes Systems, Inc. Merge to
Become Nipro Diagnostics, Inc.
6.10.2. Medtronic, Inc. Acquires New Diabetes Technology from PreciSense
AS
Table 5.3: Key Features Considered for Glucose Testing Devices
Table 5.4: Common User Errors Made While Self-Testing for Blood Glucose
Table 5.5: Compatibility of Various Blood Glucose Meters with Icodextrin
Peritoneal Dialysis (PD) Solution
Table 5.6: Ten Factors Needed to Improve the Performance of Blood Glucose
Meters
Table 5.7: Key Features Considered for Reagent Test Strips
Table 5.8: Differences between Laboratory Instruments for Glucose Analysis
and Hand-Held Blood Glucose Meters
Table 5.9: Relationship of A1c to Average Whole Blood and Plasma Glucose
Levels
Table 5.10: Unit Sales of Homecare Lancets in the U.S., 2010-2015
Table 5.11: Unit Sales of Homecare Lancets in the E.U., 2010-2015
Table 5.12: Dollar Sales of Homecare Lancets in the U.S., 2010-2015
Table 5.13: Dollar Sales of Homecare Lancets in the E.U., 2010-2015
Table 5.14: Unit Sales of Homecare Glucose Self-Testing Lancets in the
U.S., 2010-2015
Table 5.15: Unit Sales of Homecare Glucose Self-Testing Lancets in the
E.U., 2010-2015
Table 5.16: Competition in the Lancet Market Segment
Table 5.17: Limitations of Urine Glucose Monitoring
Table 5.18: Advantages of Urine Glucose Monitoring
Table 5.19: Blood Ketone Reading Indications
Table 6.1: Current Blood Glucose Self-testing Meters: Sample Size, Test
Time, and Other Features
Table 6.2: Hand-Held Blood Glucose or Blood Gas Meters Marketed for
Professional Use
Table 6.3: Clinical Blood Chemistry Analyzers with Glucose Assays
Table 6.4: Detailed Features of Selected CGM Systems Currently Available
Table 6.5: Non-Invasive Glucose Monitoring Systems in Development
Table 7.1: POC Procedural Advantages for Hospital Testing
Table 7.2: Medicare Billing Guidelines for Multi-Channel Chemistry Tests
Table 7.3: Financial Comparison for Moderate and Waived CLIA Labs
Table 8.1: Data Entry and Data Management Features to Include in Future
Meters
Table 8.2: Leading World Patient Monitoring Products in the U.S. Market
Table 8.3: Customized Reports Must Support CAP and JCAHO Requirements
Table 9.1: Abaxis Blood Analysis Diagnostic Tests
Table 9.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers
Table 9.3: Products Marketed by Abbott in the Diagnostic Market
Blood Glucose Testing and Diabetes Management published by Trimark Publications in June 1, 2012. This report consists of 262 Pages and the price starts from US $ 3400.
The contents of this page may be different from the latest version. Please contact us for details.
